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Background  and  purpose:  Metabolic  syndrome  (MetS)  and  chronic  kidney  disease  (CKD)  have  both  been
reported  as  risk  factors  for cardiovascular  events.  The  aim  of this  study  was  to assess  the  synergistic  effect
of  MetS  and CKD  on  atherosclerotic  plaque  and  cardiovascular  outcomes.
Methods  and  subjects:  A  total  of 545  consecutive  patients  who  underwent  percutaneous  coronary  inter-
vention  (PCI)  were  divided  into  4  groups  based  on  the presence  or absence  of MetS  and  CKD.  MetS  was
deﬁned  using  the  criteria  of  the Adult  Treatment  Panel  III  of the  US  National  Cholesterol  Education  Pro-
gram.  CKD  was  deﬁned  as  an  estimated  glomerular  ﬁltration  rate  of  <60  ml/min/1.73  m2. We  analyzed
the  incidence  of major  adverse  cardiac  events  (MACE),  including  cardiovascular  death,  nonfatal  myocar-
dial infarction,  target  lesion  revascularization,  and  revascularization  for new  lesions.  We  also  assessed
coronary  plaque  characteristics  of  204  patients  using  integrated  backscatter  intravascular  ultrasound
(IB-IVUS).
Results:  MACE  occurred  more  frequently  in  patients  with  both  MetS  and  CKD  (51.4%)  than  in the  other
groups,  during  the  follow-up  period  (log-rank  p  <  0.001). In  the  IB-IVUS  analyses,  patients  with  both  MetS
and CKD  exhibited  greater  plaque  burden  (p  =  0.003)  with  higher  lipid  content  (p  = 0.048)  compared  to
the  other  groups.  In Cox  analysis,  both  MetS  and  CKD  proved  to be  independent  predictors  of  MACE  even
after  adjustment  for confounding  factors  (p  = 0.018).
Conclusions:  Comorbidity  of  MetS  and  CKD  is  an  independent  predictor  of  adverse  cardiovascular  out-
comes  in  patients  undergoing  coronary  intervention,  an  effect  that  may  be attributed  to coronary  plaque
2  Jap
instability.
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Metabolic syndrome (MetS) [1–4] and chronic kidney disease
CKD) [5–8] have been reported to be risk factors for cardiovascular
vents, and MetS per se has been shown to be a signiﬁcant risk
actor for the development of CKD [9,10].  Few studies, however,
ave examined the relevance of concurrence of MetS and CKD for
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future events. Assessing the consequences of coexistence of these
clinical conditions for future adverse events is important from a
prevention perspective.
Coronary atherosclerosis is the leading cause of morbidity and
mortality in patients with coronary heart disease. Several risk
factors are associated with severity of coronary atherosclerosis,
thereby resulting in a higher incidence of cardiovascular events. The
recently developed integrated backscatter intravascular ultrasound
(IB-IVUS) allows the analysis of tissue components of coronary
plaque in vivo, and provides helpful information for the prediction
and prevention of future coronary events [11–15].
In the present study, we  assessed the prognostic impact of
concurrence of MetS and CKD in patients undergoing coronary
vier Ltd. All rights reserved.
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ntervention, taking into account coronary plaque morphology
evealed by IB-IVUS.
ubjects and methods
ubjects
This study was a prospectively planned observational investi-
ation of 550 consecutive patients who underwent percutaneous
oronary intervention (PCI) for acute coronary syndrome and stable
ngina pectoris between October 2005 and March 2008 in Chubu
osai Hospital. Of these, 4 patients were lost to follow-up and
xcluded. A total of 546 patients were included and divided into
 groups based on the presence or absence of MetS and CKD as fol-
ows: (1) MetS (−) CKD (−), n = 89; (2) MetS (−) CKD (+), n = 48; (3)
etS (+) CKD (−), n = 224; and (4) MetS (+) CKD (+), n = 185. Acute
oronary syndrome included ST-segment elevation acute myocar-
ial infarction (STEMI), non-ST segment elevation acute myocardial
nfarction (NSTEMI), and unstable angina pectoris. The diagnosis
f STEMI was based on the development of symptoms suggestive
f MI,  accompanied by an elevation in biomarker [creatine kinase
CK), CK-MB, or troponin T] levels of at least 2-fold higher than
ormal, or new signiﬁcant Q waves in 2 or more contiguous leads
16]. The diagnosis of NSTEMI was based on elevation of at least 1
ositive biomarker, characteristic electrocardiogram changes, and
 history of prolonged acute chest pain without ST segment ele-
ation. Unstable angina pectoris was deﬁned as either angina with
 progressive crescendo pattern or angina that occurred at rest.
e assessed coronary plaque characteristics using IB-IVUS data.
atients who underwent balloon angioplasty and/or angioplasty
ith atherectomy before conducting IVUS and patients with STEMI
r NSTEMI were excluded from IB-IVUS analyses. Then, IB-IVUS
mages were available in 204 consecutive patients and were divided
nto 4 groups as follows: (1) MetS (−) CKD (−), n = 50; (2) MetS (−)
KD (+), n = 35; (3) MetS (+) CKD (−), n = 67; and (4) MetS (+) CKD
+), n = 52.
Various lipid and inﬂammatory proﬁles were measured using
ommercial radioimmunoassay kits and speciﬁc immunoradio-
etric assays. For this purpose, blood samples were collected
efore PCI.
This study was  approved by the ethics committee of Chubu Rosai
ospital, and all patients provided informed consent.
eﬁnitions of MetS and CKD
MetS was deﬁned by the criteria of the Adult Treatment Panel III
f the US National Cholesterol Education Program [17]. MetS was
eﬁned as the presence of 3 or more of the following criteria: (1)
aist circumference ≥90 cm in women or ≥85 cm in men; (2) high-
ensity lipoprotein cholesterol <50 mg/dl in women or <40 mg/dl
n men; (3) serum triglycerides ≥150 mg/dl; (4) known hyperten-
ion or blood pressure ≥130/85 mmHg; and (5) fasting glucose
100 mg/dl. The cutoff values for waist circumference were the
alues used in Japanese populations [18]. Diabetes mellitus was
eﬁned as the use of any antihyperglycemic medication and was
ounted as meeting the glucose baseline. Glomerular ﬁltration rate
GFR) was estimated using the simpliﬁed modiﬁcation of the Diet
n Renal Disease Study equation [19]. In this study, CKD was deﬁned
s an estimated GFR of <60 ml/min/1.73 m2.
ndpointsThe primary endpoint was a major adverse cardiac event (MACE)
fter PCI procedure, including cardiovascular death or nonfatal
I,  and any revascularization, including target lesion revascula-
ization (TLR) and revascularization for a new lesion. The targetdiology 61 (2013) 189–195
lesion was  considered as the area covered by the stent plus 5-
mm margins proximal and distal to the edges of the stent. The
protocol recommended that multiple interventions for lesions
indicated for treatment at baseline should be performed within
30 days after the initial session. Therefore, planned revascular-
izations were excluded, but not unplanned revascularization or
other non-target events within 30 days. Any repeat revasculari-
zation, including TLR and revascularization for a new lesion, were
driven by clinical ﬁndings (presence of ischemic symptoms with
a positive functional ischemia assessment or with an ischemic
electrocardiogram change). To avoid “oculostenotic”procedures,
revascularization for which ischemia was  not proved (asymp-
tomatic or negative functional tests) was excluded. The events were
assessed by investigators blinded to the clinical data and IVUS base-
line results. For multiple occurrences of the same type of event, the
time to the ﬁrst event was considered as the time when an endpoint
was reached.
Coronary angiography and intravascular ultrasound procedure
Before performing coronary angiography and PCI, patients were
given an intracoronary dose of 0.5 mg  isosorbide dinitrate to
prevent coronary spasm. In quantitative coronary angiography, ref-
erence diameter and percent diameter stenosis were measured
by a validated automated edge-detection program (CMS-MEDIS
Medical Imaging System, Leiden, The Netherlands). IVUS catheters
(40 MHz) were inserted in target vessels as far as possible from
the index PCI procedure. Continuous ultrasound imaging was per-
formed during withdrawal of the catheter at a constant rate of
0.5 mm/s.
Measurements of conventional and IB-IVUS parameters
Conventional and IB-IVUS parameters were measured at loca-
tions with the worst plaque (plaque burden >40% in at least
3 consecutive frames) within the ﬁrst 35 mm  of the left ante-
rior descending and left circumﬂex arteries, and in the worst
plaque that could be observed by IVUS of the right coronary
artery. For conventional IVUS analysis, two-dimensional images
were quantiﬁed for lumen cross-sectional area (LCSA), exter-
nal elastic membrane (EEM), cross-sectional area (CSA), and
plaque + media (P + M)  CSA (P + M CSA = EEM CSA − LCSA) using the
IVUS system software. Eccentricity index of P + M was  calculated
as follows: (maximum P + M thickness − minimum P + M thick-
ness)/(maximum P + M thickness). Remodeling index was deﬁned
as the ratio of EEM CSA at the measured lesion (minimum luminal
site) to reference EEM CSA (average of the proximal and distal ref-
erence segments). The eccentricity index and the remodeling index
were calculated in the segment with minimal luminal area. Three-
dimensional analysis for conventional IVUS images was  performed
to compute vessel volume, lumen volume, and plaque volume (sum
of EEM CSA, LCSA, and P + M CSA at 1-mm axial intervals for the
analysis segments).
IB-IVUS analysis was performed as previously reported
[11,12,20]. In brief, a personal computer equipped with custom
software (IB-IVUS, YD Co., Nara, Japan) was connected to the
IVUS imaging system (Clear View, Boston Scientiﬁc, Natick, MA,
USA) to obtain radiofrequency signal trigger output. Ultrasound
backscattered signals were acquired using a 40-MHz (motorized
pullback 1 mm/s) mechanically rotating IVUS catheter, to be dig-
itized and subjected to spectral analysis. Integrated backscatter
values for each tissue component were calculated as an average
power using a fast Fourier transform, measured in decibels, of
the frequency component of backscattered signal from a small
volume of tissue [11,12].  Segmentation of each tissue compo-
nent was  entirely automated. Excellent correlation of IB-IVUS and
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istology has been reported in validation studies. The percent lipid
rea (lipid area/plaque area × 100) was automatically calculated by
he IB-IVUS system using commercially available software. Three-
imensional analysis of IB-IVUS images was performed for lipid
olume (sum of lipid area in each CSA at 1-mm axis intervals
f the IB-IVUS images), and the percent lipid volume (lipid vol-
me/plaque volume × 100) was calculated. Lipid-rich plaques were
eﬁned based on total plaque volume (>113.7 mm3) and percent
ipid volume (>33.7%) that were 50th percentiles of total plaque
olume and percent lipid volume.
Quantitative coronary angiography and IVUS measurements
ere conducted independently by 2 physicians who  were blinded
o the patient’s clinical characteristics.
tatistical analyses
Continuous and categorical variables are expressed as
ean ± standard deviation and proportions, respectively. Univari-
te analysis was employed to compare various clinical and IVUS
arameters among the groups, using unpaired Student’s t-test for
ontinuous normally distributed variables and Mann–Whitney
 test for non-normally distributed variables. The Bonferroni
est was performed for multiple comparisons. Chi-square and
isher’s exact tests were applied when appropriate for categorical
ariables. Event-free survival rates for clinical events among the
roups were examined using the Kaplan–Meier method, and the
ifferences in survival rates among the 4 groups were compared
sing the log-rank test. Cox proportional hazards models were
pplied to assess univariate and multivariate covariates associated
ith progression of all patients to clinical events. Multivariate Cox
roportional hazards analysis was applied to study the predictors
f clinical events adjusting for confounding factors (age, sex, body
able 1
aseline characteristics of patients.
MetS(−) CKD(−) n = 89 MetS(−) CKD
Age, (years) 70 ± 10 76.5 ± 10 
Male,  n (%) 61 (69) 22 (46) 
Waist  circumference (cm) 81 ± 8 78 ± 8
Body  mass index (kg/m2) 22.0 ± 3.2 20.8 ± 3.0 
LDL-cholesterol (mg/dl) 116 ± 30 109 ± 33 
HDL-cholesterol (mg/dl) 50.3 ± 11.9 49.4 ± 15.4 
Triglyceride (mg/dl) 105 ± 52 97 ± 47 
C-reactive protein (mg/l) 0.30 ± 0.36 0.37 ± 0.53 
Fasting glucose (mg/dl) 105 ± 34 108 ± 41 
Serum Crea, mg/dl 0.73 ± 0.18 1.82 ± 2.01 
Estimated GFR (ml/min/1.73 m2 ml/min) 80 ± 19 37 ± 16 
Ejection fraction, % 62 ± 15 61 ± 13 
BNP,  pg/ml 203 ± 297 412 ± 914 
Clinical history
Diabetes, n (%) 27 (30) 16 (33) 
Hypertension, n (%) 49 (55) 30 (63) 
Current smoking, n (%) 21 (24) 3 (6) 
Previous myocardial infarction, n (%) 18 (20) 11 (23) 
Acute  coronary syndrome, n (%) 37 (42) 25 (52) 
Multiple vessel disease, n (%) 34 (38) 20 (42) 
Previous PCI, n (%) 16 (18) 10 (21) 
Previous CABG, n (%) 7 (8) 3 (6) 
Hemodialysis, n (%) 0 (0) 6 (13) 
Medication
Aspirin, n (%) 69 (78) 40 (83)
Thienopyridine derivative, n (%) 29 (33) 18 (38) 
Statins, n (%) 37 (42) 20 (42) 
Calcium channel blocker, n (%) 24 (27) 18 (38) 
-blockers, n (%) 38 (43) 16 (33) 
ACE  inhibitor or ARB, n (%) 37 (42) 21 (44) 
Insulin, n (%) 6 (7) 1 (2) 
ata are expressed as mean ± SD or number (percentage) of patients.
CE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; BNP, brain 
isease; GFR, glomerular ﬁltration rate; HDL, high-density lipoprotein; LDL, low-density 
erum Crea, serum creatinine.diology 61 (2013) 189–195 191
mass index, and current smoking) according to the univariate
analysis for each event. All variables with p < 0.10 on univariate
analysis were considered in the multivariate model. A p < 0.05
was considered as statistically signiﬁcant. Kaplan–Meier analysis
was performed using MEDCALC (version 12.3.0, MedCalc Software
bvba, Mariakerke, Belgium). The other statistical analyses were
performed using PASW statistics (version 17.0. SPSS Inc., Chicago,
IL, USA).
Results
Baseline characteristics
Baseline characteristics of patients are presented in Table 1.
There were signiﬁcant differences in age, body mass index, low-
density lipoprotein cholesterol, ejection fraction, brain natriuretic
peptide, current smoking, acute coronary syndrome, hemodialysis,
statin, calcium channel blocker, and insulin among the 4 groups,
in addition to expected differences in MetS components, eGFR, and
serum creatinine.
Clinical outcomes
Clinical follow-up data were obtained from all enrolled patients.
Fig. 1 shows the Kaplan–Meier survival curve for the composite
end point of MACE. During the median follow-up period of 1510
days, the incidences of the primary end point deﬁned as cardio-
vascular death or nonfatal myocardial infarction, and any repeat
revascularization, were 24.7% in MetS(−)  CKD(−), 27.1% in MetS(−)
CKD (+), 37.1% in MetS(+) CKD(−), and 51.4% in MetS(+) CKD(+) by
Kaplan–Meier survival rate (p < 0.001; Table 2). In the multivari-
ate model, including hemodialysis, insulin use, multivessel disease,
(+) n = 48 MetS(+) CKD(−) n = 224 MetS(+) CKD(+) n = 185 p-value
66 ± 9 73 ± 8 <0.001
158 (71) 114 (62) 0.067
89 ± 10 88 ± 9 <0.001
24.4 ± 3.2 24.0 ± 2.9 <0.001
128 ± 37 118 ± 30 <0.001
45.8 ± 13.9 43.0 ± 13.0 <0.001
168 ± 96 151 ± 83 <0.001
0.51 ± 3.24 0.42 ± 0.51 0.87
133 ± 45 134 ± 51 <0.001
0.76 ± 0.17 1.68 ± 1.81 <0.001
79 ± 20 39 ± 15 <0.001
67 ± 12 62 ± 15 <0.001
72 ± 143 254 ± 422 <0.001
114 (51) 113 (61) <0.001
176 (79) 165 (89) <0.001
70 (31) 36 (19) 0.001
34 (15) 35 (19) 0.49
58 (26) 44 (24) <0.001
111 (50) 99 (54) 0.085
61 (27) 52 (28) 0.24
21 (9) 21 (11) 0.66
0 (0) 18 (10) <0.001
196 (88) 162 (88) 0.15
77 (35) 72 (39) 0.65
125 (56) 79 (43) 0.042
88 (39) 87 (47) 0.017
88 (39) 89 (48) 0.18
108 (48) 103 (57) 0.13
14 (6) 42 (22) <0.001
natriuretic peptide; CABG, coronary artery bypass grafting; CKD, chronic kidney
lipoprotein; MetS, metabolic syndrome; PCI, percutaneous coronary intervention;
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Fig. 1. Kaplan–Meier survival curve for the composite end point of MACE. The 4-year
rates for primary end point were 24.7% in MetS(−) CKD(−), 27.1% in MetS(−) CKD
(+), 37.1% in MetS(+) CKD(−), and 51.4% in MetS(+) CKD(+) (p < 0.001) CKD, chronic
kidney disease; MACE, major adverse cardiac event; MetS, metabolic syndrome.
Table 2
MACE during follow-up period.
Clinical event MetS(−) CKD(−) MetS(−) CKD
Total 22 (24.7%) 13 (27.1%) 
Cardiac death or MI 3 (3.4%) 5 (10.4%) 
Any  revascularization 21 (23.6%) 8 (16.7%) 
TLR  11 (12.4%) 6 (12.5%) 
Revascularization for new lesion 13 (14.6%) 2 (4.2%) 
Values in parentheses indicate event rate by Kaplan–Meier analysis. CKD, chronic kidn
myocardial infarction; TLR, target lesion revascularization.
Table 3
Predictive values for clinical outcome by Cox analysis.
Univariate 
HR (95%CI) 
MACE
Group (vs MetS−CKD−)
MetS−CKD+ 1.212 (0.618–2.408) 
MetS+CKD−  1.513 (0.945–2.422) 
MetS+CKD+ 2.395 (1.506–3.809)
Hemodialysis, yes/no 2.716 (1.650–4.470) 
Multi vessel disease, yes/no 1.335 (1.019–1.750) 
Cardiac death or MI
Group (vs MetS−CKD−)
MetS−CKD+ 3.312 (0.791–13.865) 
MetS+CKD−  0.956 (0.247–3.699) 
MetS+CKD+ 4.025 (1.199–13.510) 
Male, yes/no 1.945 (0.886–4.268) 
Any  revascularization
Group (vs MetS−CKD−)
MetS−CKD+ 0.796 (0.353–1.799) 
MetS+CKD−  1.603 (0.993–2.588) 
MetS+CKD+ 2.051 (1.266–3.322) 
Hemodialysis, yes/no 2.552 (1.323–4.922) 
Target lesion revascularization
Group (vs MetS−CKD−)
MetS−CKD+ 1.138 (0.420–3.080) 
MetS+CKD−  1.660 (0.858–3.209) 
MetS+CKD+ 1.776 (0.904–3.491) 
Hemodialysis, yes/no 2.649 (1.281–5.475) 
Multi vessel disease, yes/no 2.108 (1.390–3.195) 
Revascularization for new lesion
Group (vs MetS−CKD−)
MetS−CKD+ 0.326 (0.073–1.446) 
MetS+CKD−  1.321 (0.709–2.460) 
MetS+CKD+ 2.273 (1.239–4.172) 
Hemodialysis, yes/no 2.528 (1.226–5.211) 
CI, conﬁdential interval; CKD, chronic kidney disease; HR, hazard ratio; MetS, metabolic sdiology 61 (2013) 189–195
acute coronary syndrome at baseline, age, sex, and body mass index,
the concurrence of MetS and CKD [odds ratio (OR) 2.00, 95% con-
ﬁdence interval (CI) 1.13 − 3.54, p = 0.018], hemodialysis (OR 2.01,
95% CI 1.11 − 3.63, p = 0.022), and multivessel disease (OR 1.34, 95%
CI 1.04 − 1.77, p = 0.040) were independent predictors of total MACE
(Table 3). Cardiovascular death or nonfatal MI  was  observed in
3.4% in MetS(−)  CKD(−), 10.4% in MetS(−)  CKD (+), 3.1% in MetS(+)
CKD(−), and 11.4% in MetS(+) CKD(+) by Kaplan–Meier survival rate
(p = 0.001; Table 2). Repeat revascularization was needed in 23.6%
in MetS(−)  CKD(−), 16.7% in MetS(−)  CKD (+), 37.5% in MetS(+)
CKD(−), and 42.2% in MetS(+) CKD(+) by Kaplan–Meier survival rate
(p = 0.003; Fig. 2).
Analysis of coronary plaques
Table 4 shows data for quantitative coronary angiography and
IVUS. Concurrence of MetS and CKD was  signiﬁcantly associated
with greater plaque burden with higher lipid content as com-
pared to the other groups (Fig. 3). On logistic regression analysis,
even after adjustment for confounding factors, MetS with CKD
(OR = 2.27, p = 0.035), sex (OR = 3.45, p = 0.0023), and multivessel
(+) MetS(+) CKD(−) MetS(+) CKD(+) p-value
83 (37.1%) 95 (51.4%) <0.001
7 (3.1%) 21 (11.4%) 0.001
84 (37.5%) 78 (42.4%) 0.003
46 (20.5%) 36 (19.5%) 0.27
42 (18.8%) 53 (28.6%) <0.001
ey disease; MACE, major adverse cardiac events;MetS, metabolic syndrome; MI,
Multivariate
p-value HR (95%CI) p-value
0.58 1.089 (0.479–2.479) 0.84
0.085 1.850 (1.061–3.227) 0.030
<0.001 1.996 (1.126–3.541) 0.018
<0.001 2.005 (1.107–3.633) 0.022
0.036 1.339 (1.014–1.769) 0.04
0.10 1.797 (0.108–29.785) 0.68
0.95 1.250 (0.283–5.513) 0.77
0.024 3.363 (0.649–17.424) 0.15
0.097 3.115 (1.109–8.748) 0.031
0.58 0.863 (0.362–2.055) 0.74
0.053 1.881 (1.075–3.291) 0.027
0.003 1.910 (1.108–3.293) 0.020
<0.001 2.287 (1.299–4.027) 0.004
0.80 1.405 (0.447–4.418) 0.56
0.13 1.397 (0.674–2.892) 0.37
0.096 1.422 (0.599–3.377) 0.43
0.009 3.070 (1.308–7.207) 0.010
<0.001 2.087 (1.347–3.235) 0.001
0.14 0.330 (0.070–1.551) 0.16
0.38 1.663 (0.781–3.541) 0.19
0.008 2.190 (1.137–4.218) 0.019
0.012 2.515 (1.160–5.451) 0.019
yndrome; MACE, major adverse cardiac events; MI,  myocardial infarction.
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Fig. 2. Kaplan–Meier survival curve for any revascularization. Repeat revasculari-
zation was  needed in 23.6% in MetS(−) CKD(−), 16.7% in MetS(−)  CKD (+), 37.5%
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patients with MetS exhibited increased risk for CKD over 9 years of
T
Q
V
sn  MetS(+) CKD(−), and 42.2% in MetS(+) CKD(+) (p = 0.003). CKD, chronic kidney
isease; MetS, metabolic syndrome.
isease (OR = 2.67, p = 0.010) proved to be independent predictors
or lipid-rich plaques (Table 5).
iscussion
Increased atherosclerotic plaque in patients with MetS is not
urprising, because each component of MetS has been well estab-
ished as a risk factor for cardiovascular disease [20–23].  Similarly,
ssociation of increased atherosclerotic plaque with CKD has also
een reported [24–26].  However, limited data are available to
ssess the synergistic effects of MetS and CKD on atherosclerotic
laque, and on future outcomes. In our study, we showed that the
oncurrence of MetS and CKD was an independent predictor for
ACEs. Furthermore, the total plaque volume and the percent lipid
olume were signiﬁcantly increased in the MetS with CKD group.
able 4
uantitative coronary angiography and intravascular ultrasound results.
MetS(−) CKD(−) (n = 50) MetS(−) CKD(+
QCA analysis
Reference diameter, mm 2.48 ± 0.60 2.33 ± 0.50 
Diameter stenosis, % 66.1 ± 10.0 67.3 ± 9.1 
Conventional IVUS analysis
Vessel area, mm2 9.4 ± 3.5 9.5 ± 3.2 
Lumen area, mm2 2.2 ± 0.8 2.2 ± 0.8 
Plaque area, mm2 7.2 ± 3.0 7.3 ± 2.9 
Eccentricity index 0.57 ± 0.15 0.57 ± 0.19 
Remodeling index 0.89 ± 0.16 0.87 ± 0.16 
Vessel volume, mm3 171.9 ± 79.8 204.8 ± 151.5 
Lumen volume, mm3 64.5 ± 28.4 74.1 ± 54.0 
Plaque volume, mm3 105.4 ± 53.1 130.7 ± 100.7 
Plaque volume, % 77.5 ± 121.2 62.2 ± 7.0 
Vessel volume/lesion length, mm2 11.0 ± 3.1 11.0 ± 3.1 
Lumen volume/lesion length, mm2 4.2 ± 1.2 4.1 ± 1.0 
Plaque volume/lesion length, mm2 6.7 ± 2.2 7.0 ± 2.4 
IB  IVUS
Fibrous area, % 66.5 ± 11.3 66.1 ± 11.5 
Lipid  area, % 26.6 ± 14.0 26.5 ± 15.0 
High  signal area, % 7.0 ± 5.4 7.5 ± 5.9 
Fibrous volume, % 61.7 ± 10.6 60.2 ± 10.2 
Lipid  volume, % 31.4 ± 13.3 31.5 ± 13.6 
High  signal volume, % 5.9 ± 4.8 6.6 ± 4.7 
alues are expressed as mean ± SD. CKD, chronic kidney disease; IB-IVUS, integrated bac
yndrome; QCA, quantitative coronary angiography.diology 61 (2013) 189–195 193
Synergistic effects of MetS and CKD on coronary plaque instability
It has been well established that vulnerable plaques caused by
acute coronary syndrome are associated with increased plaque
burden, including increased pools of lipid-rich plaques. We  have
recently reported an association of lipid-rich plaques, measured
by IB-IVUS, with future adverse coronary events in patients who
underwent coronary intervention [27]. From the present results,
the presence of MetS or CKD alone was not necessary associated
with greater plaque burden with lipid-rich content. However, both
MetS and CKD had greater plaque burden with lipid-rich content
in the coronary arteries and had a higher incidence of revasculari-
zation for new lesions as compared to their counterparts. These
observations are consistent with our previous report, showing
the association between lipid-rich plaque and future non-target
ischemic events and also highlight the importance of the comor-
bidity of MetS and CKD in terms of coronary plaque instability.
Synergistic effects of MetS and CKD on future adverse events
Our study demonstrated that MetS with CKD enhances the
prognostic value of MACEs in patients who underwent coronary
intervention, as compared to MetS or CKD alone. Several studies
have demonstrated that the concurrence of MetS and CKD is associ-
ated with worse cardiovascular outcomes [28–30].  Iwashima et al.
[28] studied 1160 essential hypertensive patients for an average
of 4.8 years and found that the presence of both MetS and CKD
was associated with a 3.58-fold higher risk of cardiovascular events
compared to patients without MetS and CKD. Martin et al. [29]
studied 13,115 individuals aged ≥35 years from the third National
Health and Nutrition Examination Surveys (NHANES III) and found
that the coexistence of MetS and CKD was  associated with a 3.23-
fold higher risk of cardiovascular mortality compared to individuals
without Mets and CKD. On the other hand, previous cross-sectional
studies have suggested that MetS per se is a signiﬁcant risk factor
for the development of CKD [9,10,31]. Kurella et al. [10] found thatfollow-up in the Atherosclerosis Risk in Communities study. Chen
et al. [31] demonstrated that patients with MetS had a 2.6-fold
higher risk of prevalence of CKD in the NHANES III. Although direct
) (n = 35) MetS(+) CKD(−) (n = 67) MetS(+) CKD(+) (n = 52) p-value
2.42 ± 0.65 2.47 ± 0.76 0.72
64.8 ± 10.5 66.4 ± 10.9 0.68
10.5 ± 3.7 11.8 ± 4.7 0.0082
2.3 ± 0.8 2.7 ± 1.1 0.016
8.2 ± 3.6 9.2 ± 4.3 0.029
0.57 ± 0.18 0.53 ± 0.17 0.61
0.89 ± 0.19 0.87 ± 0.18 0.89
230.2 ± 143.1 293.5 ± 207.4 0.00060
86.2 ± 54.1 105.6 ± 70.4 0.0012
142.6 ± 97.0 174.4 ± 119.7 0.0031
60.6 ± 9.3 60.2 ± 11.6 0.41
11.8 ± 3.6 13.6 ± 5.3 0.0025
4.5 ± 1.6 5.1 ± 2.3 0.0060
7.2 ± 2.5 8.1 ± 3.6 0.042
62.4 ± 11.4 59.6 ± 14.4 0.020
31.5 ± 14.8 35.1 ± 17.4 0.019
6.6 ± 7.5 5.6 ± 5.7 0.54
59.0 ± 11.0 55.6 ± 11.2 0.036
34.3 ± 14.6 38.4 ± 14.6 0.048
5.7 ± 4.6 4.7 ± 4.0 0.12
kscatter intravascular ultrasound; IVUS, intravascular ultrasound; MetS, metabolic
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Fig. 3. Analysis of atherosclerotic coronary plaques. (A) Total plaque volume. Total plaque volume was  signiﬁcantly increased in the MetS(+) CKD(+) group (174.4 ± 119.7 mm3)
as  compared to the other groups (105.4 ± 53.1 mm3, 130.7 ± 100.7 mm3, and 142.6 ± 97.0 mm3; p = 0.003). (B) Percent lipid volume. Percent lipid volume was signiﬁcantly
increased in the MetS(+) CKD(+) group (38.4 ± 14.6%) as compared to the other groups (31.6 ± 13.0%, 31.8 ± 13.2%, and 34.3 ± 14.6%; p = 0.048). CKD, chronic kidney disease;
MetS,  metabolic syndrome.
Table 5
Simple and multiple logistic regression model for lipid-rich plaques.
Variable Simple logistic regression Multiple logistic regression
Coefﬁcient (95%CI) Odds ratio p-value Coefﬁcient (95%CI) Odds ratio p-value
MetS + CKD 0.832 (1.191–4.434) 2.30 0.013 0.819 (1.059–4.863) 2.27 0.035
ACS 0.602 (0.912–3.654) 1.83 0.089 0.545 (0.777–3.827) 1.72 0.18
Multivessel disease 1.006 (1.383–5.404) 2.73 0.004 0.980 (1.261–5.633) 2.67 0.010
CRP  0.381 (0.963–2.223) 1.46 0.075 0.301 (0.865–2.110) 1.35 0.19
Male  0.969 (1.289–5.384) 2.63 0.008 1.246 (1.558–7.761) 3.45 0.002
Age  0.003 (0.970–1.037) 1.00 0.87 0.012 (0.972–1.054) 1.01 0.56
BMI 0.056 (0.957–1.169) 1.06 0.27 0.067 (0.948–1.206) 1.07 0.28
L percen
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tipid-rich plaques were deﬁned based on total plaque volume (>113.7 mm3) and 
ercent  lipid volume. The model was adjusted for age and conventional coronary ri
CS,  acute coronary syndrome; BMI, body mass index; CKD, chronic kidney disease
orrelation of coronary plaque morphology with each event was
ot assessed in the study, our ﬁndings suggest the importance of
tricter management of MetS components, for the goal of stabi-
izing coronary plaques by lifestyle modiﬁcation or pharmacologic
ntervention to prevent future adverse coronary events.
Based on our ﬁndings, we suggest that a large plaque burden
ith lipid-rich content in patients with both MetS and CKD might
ontribute to adverse cardiovascular outcomes, thereby necessi-
ating stricter management of these patients to stabilize coronary
laques. Further prospective studies are needed to evaluate this
ypothesis.
tudy limitations
Several limitations of this study should be emphasized. First,
he design was single-center and the study population, relatively
mall. Second, coronary plaque morphology was not assessed by IB-
VUS in patients with STEMI, because thrombus formation, which
s often observed in these patients, was not color coded and
nalyzed, thereby hindering accurate calculation of plaque compo-
ents. Finally, the observational nature of this study did not allow us
o make deﬁnitive conclusions regarding the association betweent lipid volume (>33.7%), which were 50th percentiles of total plaque volume and
tors (sex, body mass index, current smoking, and LDL).
 C-reactive protein; MetS, metabolic syndrome.
plaque characteristics and cardiovascular events. Our ﬁndings need
further conﬁrmation to determine therapeutic implications.
Conclusion
Comorbidity of MetS and CKD is an independent predictor of
adverse cardiovascular outcomes in patients undergoing coronary
intervention, an effect that may  be attributed to coronary plaque
instability.
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